Pharmacyclics Inc. Hits New 52-Week High at $143.34 (PCYC)
Shares of Pharmacyclics (NASDAQ:PCYC) hit a new 52-week high during trading hours on Friday, AR Network reports. The company traded as high as $143.34 and last traded at $140.59, with a volume of 698,856 shares trading hands. The stock had previously closed at $135.82.
Several analysts have recently commented on the stock. Analysts at Wells Fargo & Co. initiated coverage on shares of Pharmacyclics (NASDAQ:PCYC) in a research note to investors on Friday. They set an “outperform” rating on the stock. Separately, analysts at JPMorgan Chase & Co. initiated coverage on shares of Pharmacyclics (NASDAQ:PCYC) in a research note to investors on Thursday, September 26th. They set an “overweight” rating and a $170.00 price target on the stock. Finally, analysts at Deutsche Bank initiated coverage on shares of Pharmacyclics (NASDAQ:PCYC) in a research note to investors on Thursday, September 26th. They set a “buy” rating and a $170.00 price target on the stock. Five investment analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. The company currently has an average rating of “Buy” and an average price target of $127.44.
Pharmacyclics has a 52-week low of $44.91 and a 52-week high of $141.77. The stock has a 50-day moving average of $119.7 and a 200-day moving average of $96.32. The company has a market cap of $10.211 billion and a P/E ratio of 132.12.
Pharmacyclics (NASDAQ:PCYC) last announced its earnings results on Wednesday, July 31st. The company reported $0.26 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.07) by $0.33. The company had revenue of $54.70 million for the quarter, compared to the consensus estimate of $52.00 million. Analysts expect that Pharmacyclics will post $-0.12 EPS for the current fiscal year.
Pharmacyclics, Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing small-molecule drugs for the treatment of cancer and immune mediated diseases.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.